D. Hunninghake

发表

National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)

J. Mckenney, M. Proschan, S. Grundy, 2002 .

Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)

J. Mckenney, M. Weinstein, S. Grundy, 1993, JAMA.

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).

J. Mckenney, S. Grundy, R. Cooper, 2001, JAMA.

Habitual Physical Activity and High‐density Lipoprotein Cholesterol in Men with Primary Hypercholesterolemia: The Lipid Research Clinics Coronary Primary Prevention Trial

D. Gordon, D. Hunninghake, C. Glueck, 1982, Circulation.

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.

S. Grundy, J. Cleeman, Sidney C. Smith, 2004, Arteriosclerosis, thrombosis, and vascular biology.

The cholesterol facts. A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. A joint statement by the American Heart Association and the National Heart, Lung, and Blood Institute

A. Gotto, S. Grundy, M. Weisfeldt, 1990 .

Recruitment experience in clinical trials: literature summary and annotated bibliography.

D. Hunninghake, J. Probstfield, D B Hunninghake, 1987, Controlled clinical trials.

Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel.

Daniel Steinberg, D. Roger Illingworth, Gustav Schonfeld, 1988, Archives of internal medicine.

Peripheral arterial disease detection, awareness, and treatment in primary care.

M. Criqui, M. McDermott, D. Hunninghake, 2001, JAMA.

Effects of fluvastatin (XU 62-320), an HMG-CoA reductase inhibitor, on the distribution and composition of low density lipoprotein subspecies in humans.

D. Hunninghake, J. Hegland, M. Tsai, 1991, Atherosclerosis.

Hypocholesterolemic effects of a dietary fiber supplement.

B. Kinosian, D. Hunninghake, J. Larosa, 1994, The American journal of clinical nutrition.

Niacin treatment increases plasma homocyst(e)ine levels.

D. Hunninghake, M. Pettinger, M. Malinow, 1999, American heart journal.

Effects of lovastatin and warfarin on early carotid atherosclerosis: sex-specific analyses. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group.

C. Furberg, W. Applegate, M. Espeland, 1999, Circulation.

Peripheral Arterial Disease in Randomized Trial of Estrogen With Progestin in Women With Coronary Heart Disease: The Heart and Estrogen/Progestin Replacement Study

J. Hsia, W. Applegate, D. Hunninghake, 2000, Circulation.

Peripheral Arterial Disease in Randomized Trial of Estrogen With Progestin in Women With Coronary Heart Disease

J. Hsia, W. Applegate, D. Hunninghake, 2000 .

Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals. 2003.

J. Mckenney, P. Barter, D. Hunninghake, 2003, Atherosclerosis. Supplements.

Long-Term Effects on Clinical Outcomes of Aggressive Lowering of Low-Density Lipoprotein Cholesterol Levels and Low-Dose Anticoagulation in the Post Coronary Artery Bypass Graft Trial

B. Hoogwerf, C. White, N. Geller, 2000 .

Lovastatin (mevinolin) in the treatment of heterozygous familial hypercholesterolemia. A multicenter study.

R. Lees, D. Hunninghake, D. Illingworth, 1987, Annals of internal medicine.

Influence of time intervals for cholestyramine dosing on the absorption of hydrochlorothiazide

D. Hunninghake, D. Hibbard, 1986, Clinical pharmacology and therapeutics.

Changes in composition and distribution of LDL subspecies in hypertriglyceridemic and hypercholesterolemic patients during gemfibrozil therapy.

D. Hunninghake, M. Tsai, J. Yuan, 1994, Atherosclerosis.

Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II).

E. Vittinghoff, J. Cauley, C. Furberg, 2002, JAMA.

Safety of rosuvastatin.

J. Kastelein, D. Hunninghake, E. Stein, 2004, The American journal of cardiology.

Controlled trial of acifran in type II hyperlipoproteinemia

D. Hunninghake, G. Sopko, R. Tosiello, 1985, Clinical pharmacology and therapeutics.

Effect of colestipol and clofibrate on plasma lipid and lipoproteins in type IIa hyperlipoproteinemia.

D. Hunninghake, J. Probstfield, L. Crow, 1981, Metabolism: clinical and experimental.

Effect of an Aggressive Lipid-Lowering Strategy on Progression of Atherosclerosis in the Left Main Coronary Artery From Patients in the Post Coronary Artery Bypass Graft Trial

B. Hoogwerf, C. White, N. Geller, 2001, Circulation.

Effects of celiprolol and other antihypertensive agents on serum lipids and lipoproteins.

D. Hunninghake, D. Hunninghake, 1991, American heart journal.

The effects of cardioselective vasodilating β-blockers on lipids

D. Hunninghake, 1991 .

Comparison of effectiveness of thyrotropin-suppressive doses of D- and L-thyroxine in treatment of hypercholesterolemia.

D. Hunninghake, C. Mariash, J. Bantle, 1984, The American journal of medicine.

Alterations of plasma lipid and lipoprotein levels associated with benzodiazepine use--the LRC Program Prevalence Study.

E. Barrett-Connor, P. Wahl, R. Wallace, 1981, Atherosclerosis.

Effect of colestipol and clofibrate, singly and in combination, on plasma lipid and lipoproteins in type IIb hyperlipoproteinemia.

D. Hunninghake, C. Bell, L. Olson, 1981, Metabolism: clinical and experimental.

Alterations of Plasma High‐density Lipoprotein Cholesterol Levels Associated with Consumption of Selected Medications: The Lipid Research Clinics Program Prevalence Study

E. Barrett-Connor, P. Wahl, R. Wallace, 1980, Circulation.

Drug Treatment of Type II Hyperlipoproteinemia. Effects on Plasma Lipid and Lipoprotein Levels

D. Hunninghake, 1980 .

Effect of probucol on plasma lipids and lipoproteins in type IIb hyperlipoproteinemia.

D. Hunninghake, C. Bell, L. Olson, 1980, Atherosclerosis.

ALTERED PLASMA LIPID AND LIPOPROTEIN LEVELS ASSOCIATED WITH ORAL CONTRACEPTIVE AND ŒSTROGEN USE Report from the Medications Working Group of the Lipid Research Clinics Program

E. Barrett-Connor, R. Wallace, G. Heiss, 1979, The Lancet.

Randomized comparison of the efficacy and safety of cerivastatin and pravastatin in 1,030 hypercholesterolemic patients. The Cerivastatin Study Group.

D. Hunninghake, M. Poland, R. Knopp, 2000, Mayo Clinic proceedings.

Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. I. A dose-response study.

A. Dobs, A. Goldberg, D. Hunninghake, 1990, Atherosclerosis.

Blood Lipid Effects of Antihypertensive Therapy: A Double‐Blind Comparison of the Effects of Methyldopa and Propranolol

D. Hunninghake, R. Grimm, A. Leon, 1984, Journal of clinical pharmacology.

Effective and safe modification of multiple atherosclerotic risk factors in patients with peripheral arterial disease.

W. Applegate, J. W. Kennedy, D. Hunninghake, 2000, American heart journal.

Comparative effects of atenolol versus celiprolol on serum lipids and blood pressure in hyperlipidemic and hypertensive subjects.

A. Gotto, W. Harris, D. Hunninghake, 1993, The American journal of cardiology.

Intense dietary counseling lowers LDL cholesterol in the recruitment phase of a clinical trial of men who had coronary artery bypass grafts.

D. Hunninghake, E. Quiter, D. M. Shenberger, 1992, Journal of the American Dietetic Association.

Preferences and opinions of consumers vs dietitians on cholesterol education materials.

D. Hunninghake, D. Froberg, S. Allen, 1991, Journal of the American Dietetic Association.

Lipids and hypertension. Implications of new guidelines for cholesterol management in the treatment of hypertension.

D. Hunninghake, R. Grimm, 1986, The American journal of medicine.

Effects of thiazide diuretics on plasma lipids and lipoproteins in mildly hypertensive patients: a double-blind controlled trial.

H. Blackburn, D. Hunninghake, R. Grimm, 1981, Annals of internal medicine.

Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively.

D. Hunninghake, W. Insull, S. Burke, 2001, Atherosclerosis.

INCREASED LEUCOCYTE OXIDATIVE METABOLISM IN HYPERLIPOPROTEINAEMIA

D. Hunninghake, J. Hoidal, P. Ludwig, 1982, The Lancet.

Effects of thiazide diuretics on plasma lipids and lipo-proteins in mildly hypertensive patients: a

D. Hunninghake, R. Grimm, A. Leon, 2020 .

Rationale and design of the Arterial Disease Multiple Intervention Trial (ADMIT) pilot study.

T. Wilt, W. Applegate, D. Hunninghake, 1999, The American journal of cardiology.

The Cholesterol Facts

P. Wilson, S. Grundy, J. Cleeman, 2005 .

Lipid-Lowering Drugs in the Treatment of Atherosclerosis

D. Hunninghake, J. Peters, 1987 .

Blood lipids and lipoproteins in a Minnesota urban population.

D. Jacobs, R. Luepker, D. Hunninghake, 1980, Journal of chronic diseases.

Recruitment in NHLBI population-based studies and randomized clinical trials: data analysis and survey results.

J. Wittes, D. Hunninghake, J. Probstfield, 1987, Controlled clinical trials.

Recruitment from clinical studies.

D. Hunninghake, J. Knoke, A. Leon, 1982, Circulation.

Population characteristics according to recruitment source.

D. Hunninghake, J. Knoke, M. Ladouceur, 1982, Circulation.

Recruitment for controlled clinical trials: literature summary and annotated bibliography.

D. Hunninghake, J. Probstfield, K. Hill, 1997, Controlled clinical trials.

Aggressive Lipid-Lowering Initiation Abates New Cardiac Events (ALLIANCE)-rationale and design of atorvastatin versus usual care in hypercholesterolemic patients with coronary artery disease.

D. Hunninghake, J. Isaacsohn, M. Davidson, 2000, The American journal of cardiology.

Estrogen Replacement Therapy and Progression of Intimal-Medial Thickness in the Carotid Arteries of Postmenopausal Women

C. Furberg, W. Applegate, M. Espeland, 1995 .

The Minnesota Regional Peripheral Arterial Disease Screening Program: toward a definition of community standards of care.

D. Hunninghake, S. Krook, M. M. Lunzer, 2001, Vascular medicine.

Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: a 24-week randomized controlled trial.

D. Hunninghake, W. Insull, M. Davidson, 2001, Mayo Clinic proceedings.

Is aggressive cholesterol control justified? Review of the post-coronary artery bypass graft trial.

D. Hunninghake, 1998, The American journal of cardiology.

Clinical efficacy of cerivastatin: phase IIa dose-ranging and dose-scheduling studies.

D. Hunninghake, D. Hunninghake, 1998, American Journal of Cardiology.

Clinical Trial linical Outcomes in Managed-Care atients With Coronary Heart isease Treated Aggressively in ipid-Lowering Disease Management Clinics

D. Hunninghake, J. Koreň, 2016 .

Lipid‐Altering Efficacy and Safety of Simvastatin 80 mg/Day: Long‐Term Experience in a Large Group of Patients with Hypercholesterolemia

M. Mercuri, D. Hunninghake, E. Stein, 2000, Clinical cardiology.

Effect of fluvastatin on intermediate density lipoprotein (remnants) and other lipoprotein levels in hypercholesterolemia.

D. Hunninghake, R. Knopp, C. Walden, 1995, The American journal of cardiology.

Lipid-altering efficacy and safety of simvastatin 80 mg/day: worldwide long-term experience in patients with hypercholesterolemia.

M. Mercuri, J. Kastelein, D. Hunninghake, 2000, Nutrition, metabolism, and cardiovascular diseases : NMCD.

Postdischarge lipid management of coronary artery disease patients according to the new National Cholesterol Education Program guidelines.

D. Hunninghake, 2001, The American journal of cardiology.

Cholesterol lowering in the elderly. Results of the Cholesterol Reduction in Seniors Program (CRISP) pilot study.

D. Gordon, W. Applegate, D. Hunninghake, 1994, Archives of internal medicine.

Noncardiovascular Disease Outcomes During 6.8 Years of Hormone Therapy: Heart and Estrogen/Progestin Replacement Study Follow-Up (HERS II)

E. Vittinghoff, J. Cauley, C. Furberg, 2002 .

Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines

Neil J Stone, S. Grundy, J. Cleeman, 2004, Circulation.

Effects of lipid-altering treatment in diabetes mellitus and the metabolic syndrome.

P. Deedwania, D. Hunninghake, H. Bays, 2004, The American journal of cardiology.

Relative impact of lovastatin and estrogen replacement therapy on progression of intimal-medial thickness in the carotid arteries

C. Furberg, W. Applegate, M. Espeland, 1994 .

Rationale, design, and baseline characteristics of the Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT).

C. Furberg, B. Pitt, W. Riley, 1997, The American journal of cardiology.

Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group.

C. Furberg, W. Applegate, H. Adams, 1994, Circulation.

Estrogen replacement therapy and progression of intimal-medial thickness in the carotid arteries of postmenopausal women. ACAPS Investigators. Asymptomatic Carotid Atherosclerosis Progression Study.

C. Furberg, W. Applegate, M. Espeland, 1995, American journal of epidemiology.

34th Bethesda Conference: Can atherosclerosis imaging techniques improve the detection of patients at risk for ischemic heart disease?

L. Shaw, D. Mark, R. Virmani, 2003 .

Workshop IV--National Cholesterol Education Program guidelines: are they clinically relevant?

D. Hunninghake, 1991, The American journal of medicine.

Conflict-of-interest guidelines for a multicenter clinical trial of treatment after coronary-artery bypass-graft surgery.

B. Hoogwerf, C. White, G. Knatterud, 1989, The New England journal of medicine.

The Hemostatic Effects of Warfarin Titration in Post CABG Patients in Comparison to Placebo Treatment

B. Hoogwerf, D. Hunninghake, J. Probstfield, 2001, Journal of Thrombosis and Thrombolysis.

Hemostatic Effects of 1 mg Daily Warfarin on Post CABG Patients

D. Hunninghake, J. Probstfield, M. Terrin, 1999, Journal of Thrombosis and Thrombolysis.

Effect of histamine of lipolysis and adenosine 3',5'-monophosphate levels in canine adipose tissue.

D. Hunninghake, N. D. Goldberg, V. Grund, 1973, Biochemical pharmacology.

AHA Conference Report on Cholesterol. Drug therapy.

D. Hunninghake, R. Havel, U. Steinbrecher, 1989, Circulation.

Drug Therapy Participants

D. Hunninghake, R. Havel, U. Steinbrecher, 2022 .

Treatment of hyperlipidemia in heart transplant recipients with gemfibrozil +/- lovastatin.

D. Hunninghake, M. Olivari, S. Kubo, 1993, The American journal of cardiology.

Factors influencing the development of hypercholesterolemia after cardiac transplantation.

D. Hunninghake, R. Bolman, M. Olivari, 1992, The American journal of cardiology.

A screening survey of dyslipoproteinemias associated with prescription drug use. The Lipid Research Clinics Program Prevalence Study.

L. Chambless, E. Barrett-Connor, P. Wahl, 1986, Circulation.

Effects of One Year of Treatment with Pravastatin, an HMG‐CoA Reductase Inhibitor, on Lipoprotein a

D. Hunninghake, M. Mellies, E. Stein, 1993, Journal of clinical pharmacology.

Lessons from the post coronary artery bypass graft study in evaluating and controlling technical variability in angiographic trials. Post CABG Investigators.

B. Hoogwerf, C. White, M. Domanski, 2001, The American journal of cardiology.

Efficacy and safety of once-daily vs twice-daily dosing with fluvastatin, a synthetic reductase inhibitor, in primary hypercholesterolemia.

J. Mckenney, D. Hunninghake, J. Wright, 1994, Archives of internal medicine.

The effect of butoxamine on catecholamine‐induced metabolic changes in humans

D. Hunninghake, Daniel L. Azarnof, D. Waxman, 1966, Clinical pharmacology and therapeutics.

Alteration in blood pressures associated with combined alcohol and oral contraceptive use-the lipid research clinics prevalence study.

E. Barrett-Connor, P. Wahl, M. Criqui, 1982, Journal of chronic diseases.

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.

S. Grundy, J. Cleeman, Sidney C. Smith, 2004, Journal of the American College of Cardiology.

Long-term treatment of hypercholesterolemia with dietary fiber.

B. Kinosian, D. Hunninghake, J. Larosa, 1994, The American journal of medicine.

Colesevelam HCl (Welchol™), a new, potent, well tolerated, non systemic, lipid lowering agent

D. Hunninghake, M. Davidson, S. Burke, 2000 .

Comparative effects of prazosin and propranolol on blood lipid profiles in hypertensive, hypercholesterolemic patients. Preliminary results.

D. Hunninghake, A. Leon, J. Stoulil, 1989, The American journal of medicine.

Effect of human apolipoprotein E isoforms on plasma lipids, lipoproteins and apolipoproteins in apolipoprotein E-deficient mice.

D. Hunninghake, J. Yuan, G. Wu, 1998, Atherosclerosis.

Physiological Markers of Smoking and Their Relation to Coronary Heart Disease: The Lipid Research Clinics Coronary Primary Prevention Trial

G. Heiss, D. Hunninghake, J. Knoke, 1987, Arteriosclerosis.

Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition on human gut mucosa

D. Hunninghake, S. Ewing, R. Gebhard, 1991, Lipids.

Cholesterol-lowering effects of psyllium hydrophilic mucilloid. Adjunct therapy to a prudent diet for patients with mild to moderate hypercholesterolemia.

D. Hunninghake, T. K. Balm, L. Bell, 1989, JAMA.

Ascorbic acid supplement use and the prevalence of gallbladder disease. Heart & Estrogen-Progestin Replacement Study (HERS) Research Group.

D. Hunninghake, D. Grady, J. Simon, 1998, Journal of clinical epidemiology.

Effect of niacin, warfarin, and antioxidant therapy on coagulation parameters in patients with peripheral arterial disease in the Arterial Disease Multiple Intervention Trial (ADMIT).

W. Applegate, J. W. Kennedy, D. Hunninghake, 2000, American heart journal.

Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the post coronary artery bypass graft trial. Post CABG Investigators.

B. Hoogwerf, C. White, N. Geller, 2000, Circulation.

Treating to meet NCEP-recommended LDL cholesterol concentrations with atorvastatin, fluvastatin, lovastatin, or simvastatin in patients with risk factors for coronary heart disease.

D. Hunninghake, H. Schrott, H. Schrott, 1998, The Journal of family practice.

Alterations in clinical chemistry measures associated with oral contraceptive and estrogen use: the Lipid Research Clinics Program Prevalence Study.

E. Barrett-Connor, P. Wahl, R. Wallace, 1982, The Journal of reproductive medicine.

Simvastatin, a competitive inhibitor of HMG‐CoA reductase, lowers cholesterol saturation index of gallbladder bile

D. Hunninghake, M. Freeman, R. Gebhard, 1988, Hepatology.

A summary of implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.

S. Grundy, J. Cleeman, Sidney C. Smith, 2004, Arteriosclerosis, thrombosis, and vascular biology.

HMG CoA reductase inhibitors

D. Hunninghake, 1992 .

Rosuvastatin improves the atherogenic and atheroprotective lipid profiles in patients with hypertriglyceridemia

D. Rader, D. Hunninghake, E. Stein, 2004, Coronary artery disease.

Cystatin C is an independent predictor of fasting and post-methionine load total homocysteine concentrations among stable renal transplant recipients.

D. Hunninghake, M. Tsai, N. Hanson, 2001, Clinical chemistry.

Cimetidine blockade of histamine‐induced insulin secretion

D. Hunninghake, V. Grund, Richard Martino, 1980, Clinical pharmacology and therapeutics.

Metabolic Studies with Lovastatin in Patients with Primary Hypercholesteremia

D. Hunninghake, M. Freeman, R. Gebhard, 1987 .

Plasma concentrations of flecainide acetate, a new antiarrhythmic agent, in humans.

D. Hunninghake, J. W. Frost, A. Leon, 1984, Clinical therapeutics.

Effect of fibric acid derivatives on blood lipid and lipoprotein levels.

D. Hunninghake, J. Peters, 1987, The American journal of medicine.

Effect of Amlodipine on the Progression of Atherosclerosis and the Occurrence of Clinical Events

Michael E. Miller, C. Furberg, B. Pitt, 2000, Circulation.

Hyperlipidemia in long-term survivors of pediatric renal transplantation.

D. Hunninghake, A. Matas, A. Sharma, 1994, Clinical transplantation.

Relief of pain of Fabry's disease by diphenylhydantoin

D. Hunninghake, R. Desnick, L. Lockman, 1973, Neurology.

Pharmacologic management of triglycerides

D. Hunninghake, 1999, Clinical cardiology.

A muclticenter comparison of lovastatin and probucol for treatment of severe primary hypercholesterolemia

D. Hunninghake, R. Goldberg, E. Nikkilä, 1990 .

[9] Uracil and thymine reductases

S. Grisolía, D. Hunninghake, 1967 .

A Multiclinic Double‐Blind Comparison of Timolol and Hydrochlorothiazide Alone and in Combination in the Treatment of Essential Hypertension

D. Hunninghake, A. Leon, A. Leon, 1983, Journal of clinical pharmacology.

Determination of apolipoprotein E genotypes by single-strand conformational polymorphism.

M. Tuchman, D. Hunninghake, J. Eckfeldt, 1993, Clinical chemistry.

The pharmacology and therapeutics of lipid-lowering drugs.

D. Hunninghake, 1987, American pharmacy.

Effect of gemfibrozil on composition of lipoproteins and distribution of LDL subspecies.

D. Hunninghake, M. Tsai, J. Yuan, 1992, Atherosclerosis.

Intestinal HMG-CoA reductase activity is low in hypercholesterolemic patients and is further decreased with lovastatin therapy.

D. Hunninghake, M. Freeman, R. Gebhard, 1988, Journal of lipid research.

Aggressive cholesterol lowering delays saphenous vein graft atherosclerosis in women, the elderly, and patients with associated risk factors. NHLBI post coronary artery bypass graft clinical trial. Post CABG Trial Investigators.

N L Geller, S A Forman, B. Hoogwerf, 1999, Circulation.

Delayed progression of atherosclerosis in coronary bypass grafts is similar in women compared to men following aggressive cholesterol lowering despite more frequent risk factors: post CABG trial

B. Hoogwerf, C. White, M. Domanski, 1998 .

Lovastatin: follow-up ophthalmologic data.

I. Goldberg, D. Hunninghake, G. Schonfeld, 1988, JAMA.

Recruitment for clinical trials: the Lipid Research Clinics Coronary Primary Prevention Trial experience. Its implications for future trials.

D. Hunninghake, J. Knoke, A. Leon, 1982, Circulation.

Biotransformation of lovastatin. V. Species differences in in vivo metabolite profiles of mouse, rat, dog, and human.

D. Hunninghake, E. Ulm, D. E. Duggan, 1993, Drug metabolism and disposition: the biological fate of chemicals.

Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals.

J. Mckenney, P. Barter, D. Hunninghake, 2004, American Journal of Cardiology.

The effect of cholestyramine and colestipol on the absorption of hydrochlorothiazide.

D. Hunninghake, S. King, K. Lacroix, 1982, International journal of clinical pharmacology, therapy, and toxicology.

Postmenopausal Hormone Therapy Increases Risk for Venous Thromboembolic Disease: The Heart and Estrogen/progestin Replacement Study

E. Vittinghoff, C. Furberg, D. Hunninghake, 2000, Annals of Internal Medicine.

Peripheral Arterial Disease Detection, Awareness, and Treatment in Primary Care

M. Criqui, M. McDermott, D. Hunninghake, 2001 .

The efficacy of intensive dietary therapy alone or combined with lovastatin in outpatients with hypercholesterolemia.

W. Harris, D. Hunninghake, E. Feldman, 1993, The New England journal of medicine.

Incorporation of Lean Red Meat into a National Cholesterol Education Program Step I Diet: A Long-Term, Randomized Clinical Trial in Free-Living Persons with Hypercholesterolemia

D. Hunninghake, K. Maki, M. Davidson, 2000, Journal of the American College of Nutrition.

27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 4. Efficacy of risk factor management.

J. Cohn, D. Hunninghake, J. Forrester, 1996, Journal of the American College of Cardiology.

A sensitive and convenient micromethod for estimation of urea, citrulline, and carbamyl derivatives.

S. Grisolía, D. Hunninghake, 1966, Analytical biochemistry.

Safety of long-term large doses of aspartame.

D. Hunninghake, A. Leon, T. Tephly, 1989, Archives of internal medicine.

Alterations in human serum alkaline phosphatase and its isoenzymes by hypolipidemic agents: colestipol and clofibrate.

D. Hunninghake, J. Probstfield, B. Statland, 1983, Metabolism: clinical and experimental.

Pharmacokinetics of propylthiouracil in man after a single oral dose.

D. Hunninghake, D. Sitar, 1975, The Journal of clinical endocrinology and metabolism.

Effects of cholestyramine and colestipol on the plasma concentrations of propranolol.

D. Hunninghake, D. Hibbard, J. Peters, 1984, British journal of clinical pharmacology.

Psyllium-enriched cereals lower blood total cholesterol and LDL cholesterol, but not HDL cholesterol, in hypercholesterolemic adults: results of a meta-analysis.

C. Summerbell, M. Becker, D. Hunninghake, 1997, The Journal of nutrition.

Cholesterol-Lowering Effects of Psyllium Hydrophilic Mucilloid: Adjunct Therapy to a Prudent Diet for Patients With Mild to Moderate Hypercholesterolemia

D. Hunninghake, T. K. Balm, L. Bell, 1989 .

Inhibition of Histamine‐Stimulated Increases in Neart Rate in Man with the H2‐Histamine Receptor Antagonist Cimetidine

D. Hunninghake, V. Grund, 1981, Journal of clinical pharmacology.

Effect of Estrogen plus Progestin on Risk for Biliary Tract Surgery in Postmenopausal Women with Coronary Artery Disease: The Heart and Estrogen/progestin Replacement Study

J. Cauley, D. Hunninghake, F. Lin, 2001, Annals of Internal Medicine.

Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study.

D. Hunninghake, M. Koren, 2004, Journal of the American College of Cardiology.

Statin Therapy, Cardiovascular Events, and Total Mortality in the Heart and Estrogen/Progestin Replacement Study (HERS)

E. Vittinghoff, R. Blumenthal, D. Hunninghake, 2002, Circulation.

TSH response to TRH in euthyroid, hypercholesterolemic patients treated with graded doses of dextrothyroxine.

D. Hunninghake, J. Probstfield, J. Bantle, 1981, Metabolism: clinical and experimental.

Low‐dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low‐density lipoprotein cholesterol in patients with primary hypercholesterolemia

J. Mckenney, D. Hunninghake, J. Isaacsohn, 2001, Clinical cardiology.

Efficacy and Tolerability of Low-dose Simvastatin and Niacin, Alone and in Combination, in Patients With Combined Hyperlipidemia: A Prospective Trial

D. Hunninghake, D. Illingworth, R. Goldberg, 1996, Journal of cardiovascular pharmacology and therapeutics.

Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)

D. Hunninghake, P. Jones, S. Kafonek, 1998, The American journal of cardiology.

Therapeutic efficacy of the lipid-lowering armamentarium: the clinical benefits of aggressive lipid-lowering therapy.

D. Hunninghake, 1998, The American journal of medicine.

Effect of methylphenidate on plasma anticonvulsant levels

D. Hunninghake, H. Kupferberg, W. Jeffery, 1972, Clinical pharmacology and therapeutics.

Effect of Pharmacologic Lipid Lowering on Health‐Related Quality of Life in Older Persons: Results from the Cholesterol Reduction in Seniors Program (CRISP) Pilot Study

N. Santanello, W. Applegate, D. Hunninghake, 1997, Journal of the American Geriatrics Society.

Cholesterol Lowering in the Elderly: Results of the Cholesterol Reduction in Seniors Program (CRISP) Pilot Study

D. Gordon, W. Applegate, D. Hunninghake, 1994 .

Effects of a vigorous walking program on body composition, and carbohydrate and lipid metabolism of obese young men.

D. Hunninghake, A. Leon, R. Serfass, 1979, The American journal of clinical nutrition.

Diagnosis and treatment of lipid disorders.

D. Hunninghake, 1994, The Medical clinics of North America.

Effect of Estrogen Plus Progestin on Progression of Carotid Atherosclerosis in Postmenopausal Women With Heart Disease: HERS B-Mode Substudy

C. Furberg, W. Applegate, W. Riley, 2002, Arteriosclerosis, thrombosis, and vascular biology.

Multiple Risk Factor Intervention Trial * Brown and Goldstein ' s research on low-density lipoprotein ( LDL ) receptors * Coronary Primary Prevention Trial * Helsinki Heart Study The

P. Wilson, S. Grundy, D. Hunninghake, 2005 .

Effect of fluvastatin on intermediatedensity Lipoprotein (remnants) and other lipoprotein levels in hypercholestarolemia

D. Hunninghake, R. Knopp, C. Walden, 1995 .

Sex bias and underutilization of lipid-lowering therapy in patients with coronary artery disease at academic medical centers in the United States and Canada. Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT) Investigators.

C. Furberg, B. Pitt, R. Byington, 2000, Archives of internal medicine.

Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: A randomized trial. Arterial Disease Multiple Intervention Trial.

D. Hunninghake, J. Kostis, K. Davis, 2000, JAMA.

The Cost of Reaching National Cholesterol Education Program (NCEP) Goals in Hypercholesterolaemic Patients

J. Mckenney, D. Hunninghake, S. Weiss, 1998, PharmacoEconomics.

Carotenoids and vitamin A: the effect of hypocholesterolemic agents on serum levels.

D. Hunninghake, J. Probstfield, T. L. Lin, 1985, Metabolism: clinical and experimental.

Plasma cholesterol: an influencing factor in red blood cell oxygen release and cellular oxygen availability.

H Buchwald, T J O'Dea, T D Rohde, 2000, Journal of the American College of Surgeons.

E ffects of Aggressive Cholesterol Lowering and Low-Dose Anticoagulation on Clinical and Angiographic Outcomes in Patients With Diabetes The Post Coronary Artery Bypass Graft Tr i a l

B. Hoogwerf, C. White, M. Domanski, 1999 .

Clinical efficacy and safety of cerivastatin: summary of pivotal phase IIb/III studies.

M. Hanefeld, D. Hunninghake, W. Insull, 1998, The American journal of cardiology.

Differences in Medical Care and Disease Outcomes Among Black and White Women With Heart Disease

Mark A Hlatky, C. Furberg, A. Jha, 2003, Circulation.

Pharmacologic therapy for the hyperlipidemic patient.

D. Hunninghake, 1983, The American journal of medicine.

Human and Clinical Nutrition Psyllium-Enriched Cereals Lower Blood Total Cholesterol and LDL Cholesterol, but Not HDL Cholesterol, in Hypercholesterolemic Adults: Results of a Meta-Analysis

James W. Anderson, C. Summerbell, M. Becker, 1997 .

Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.

K. Ferdinand, D. Hunninghake, E. Stein, 2004, Clinical therapeutics.

A dose‐ranging study of a new, once‐daily, dual‐component drug product containing niacin extended‐release and lovastatin

D. Hunninghake, M. McGovern, R. Brazg, 2003, Clinical cardiology.

Drug treatment of dyslipoproteinemia.

D. Hunninghake, Donald B. Hunninghake, 1990, Endocrinology and metabolism clinics of North America.

Treatment of type III hyperlipoproteinemia with four different treatment regimens.

B. Hoogwerf, D. Hunninghake, J. Bantle, 1984, Atherosclerosis.

Cardiovascular disease in chronic obstructive pulmonary disease.

D. Hunninghake, 2005, Proceedings of the American Thoracic Society.

The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day.

D R Illingworth, D. Hunninghake, D. Illingworth, 1997, The American journal of cardiology.

A Randomized Multicenter Trial Comparing the Efficacy of Simvastatin and Fluvastatin

D. Hunninghake, D. Illingworth, E. Stein, 1996, Journal of cardiovascular pharmacology and therapeutics.

The Minnesota Regional Peripheral Arterial Disease Screening Program: toward a definition of community standards of care

D. Hunninghake, S. Krook, M. M. Lunzer, 2001 .

Comparison of the effects of lean red meat vs lean white meat on serum lipid levels among free-living persons with hypercholesterolemia: a long-term, randomized clinical trial.

D. Hunninghake, K. Maki, M. Davidson, 1999, Archives of internal medicine.

Nicotinic acid as a lipoprotein-altering agent. Therapy directed by the primary physician.

D. Hunninghake, J. Probstfield, 1994, Archives of internal medicine.

LDL-cholesterol as a determinant of coronary heart disease.

D. Hunninghake, 1990, Clinical Therapeutics.

Effect on high-density lipoprotein cholesterol of maximum dose simvastatin and atorvastatin in patients with hypercholesterolemia: results of the Comparative HDL Efficacy and Safety Study (CHESS).

C. Ballantyne, D. Hunninghake, M. Davidson, 2003, American heart journal.

Roundtable discussion: therapeutic challenges and deficiencies.

Y. Arad, R. Blumenthal, W. Boden, 2001, The American journal of cardiology.

Effects of simvastatin, an HMG‐CoA reductase inhibitor, in patients with hypertriglyceridemia

J. Mckenney, R. Krauss, A. Dobs, 2003, Clinical cardiology.

Reduction of LDL Cholesterol in Patients with Primary Hypercholesterolemia by SCH 48461: Results of a Multicenter Dose‐Ranging Study

A. Goldberg, D. Hunninghake, E. Stein, 2001, Journal of clinical pharmacology.

Effect of cimetidine on plasma lipids and lipoproteins

B. Hoogwerf, D. Hunninghake, V. Grund, 1984, Clinical pharmacology and therapeutics.

A Comparison of Simvastatin and Atorvastatin up to Maximal Recommended Doses in a Large Multicenter Randomized Clinical Trial

M. Mercuri, D. Hunninghake, D. Illingworth, 2001 .

Comparison of effects of simvastatin versus atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I levels.

J. Kastelein, M. Mercuri, J. Kastelein, 2000, The American journal of cardiology.

Sensitivity of the Canine Pancreatic Intraductal Pressure to Subclinical Reduction in Cholinesterase Activity

D. Hunninghake, R. Goodale, J. Borner, 1979, Annals of surgery.

Diuretics and Plasma Lipids: Effects of thiazides and spironolactone on blood lipids

H. Blackburn, D. Hunninghake, R. Grimm, 1982 .

Effectiveness of low-dose colestipol therapy in patients with moderate hypercholesterolemia.

P. Greenland, W. Haskell, D. Hunninghake, 1992, The American journal of cardiology.

Comparative effects of simvastatin and atorvastatin in hypercholesterolemic patients with characteristics of metabolic syndrome.

C. Ballantyne, D. Hunninghake, B. Gumbiner, 2003, Clinical therapeutics.

Cholesterol-lowering effects of soluble-fiber cereals as part of a prudent diet for patients with mild to moderate hypercholesterolemia.

D. Hunninghake, L. Bell, H. Reynolds, 1990, The American journal of clinical nutrition.

Effects of aggressive cholesterol lowering and low-dose anticoagulation on clinical and angiographic outcomes in patients with diabetes: the Post Coronary Artery Bypass Graft Trial.

B. Hoogwerf, C. White, M. Domanski, 1999, Diabetes.

Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. II. Once-daily versus twice-daily dosing.

A. Goldberg, D. Hunninghake, J. Kostis, 1990, Atherosclerosis.

Whole Grain Oat Cereal Lowers Serum Lipids

D. Hunninghake, E. Quiter, H. Reynolds, 2000 .

Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome.

P. Deedwania, D. Hunninghake, H. Bays, 2005, The American journal of cardiology.

Histamine-induced lipid mobilization in humans and dogs.

D. Hunninghake, V. Grund, E. Pollack, 1976, The Journal of pharmacology and experimental therapeutics.

Histamine receptors in adipose tissue: involvement of cyclic adenosine monophosphate and the H2-receptor in the lipolytic response to histamine in isolated canine fat cells.

D. Hunninghake, N. D. Goldberg, V. Grund, 1975, The Journal of pharmacology and experimental therapeutics.

Comparison of the efficacy of atorvastatin versus cerivastatin in primary hypercholesterolemia.

D. Hunninghake, W. Insull, M. Davidson, 2001, The American journal of cardiology.

A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial.

M. Mercuri, D. Hunninghake, D. Illingworth, 2001, Current medical research and opinion.

Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication.

J. Crouse, D. Hunninghake, M. Elam, 1998, Arteriosclerosis, thrombosis, and vascular biology.

Plasma homocysteine levels in living kidney donors before and after uninephrectomy.

P. Woll, D. Hunninghake, A. Matas, 2004, The Journal of laboratory and clinical medicine.

Fenofibrate for the treatment of type IV and V hyperlipoproteinemias: a double-blind, placebo-controlled multicenter US study.

A. Goldberg, D. Hunninghake, E. Feldman, 1989, Clinical therapeutics.

Comparison of health-related quality-of-life outcomes of men and women after coronary artery bypass surgery through 1 year: findings from the POST CABG Biobehavioral Study.

B. Hoogwerf, G. Knatterud, D. Hunninghake, 2003, American heart journal.

Angiographic changes in saphenous vein grafts are predictors of clinical outcomes.

B. Hoogwerf, C. White, M. Domanski, 2003, American heart journal.

The Eating Pattern Assessment Tool: a simple instrument for assessing dietary fat and cholesterol intake.

R. Mullis, D. Hunninghake, M. Brekke, 1994, Journal of the American Dietetic Association.

The lipid clinic concept

R. Varco, D. Hunninghake, H. Buchwald, 1970 .

Postmenopausal Hormone Therapy Increases Risk for Venous Thromboembolic Disease: The Heart and Estrogen/progestin Replacement Study

E. Vittinghoff, C. Furberg, D. Hunninghake, 2000, Annals of Internal Medicine.

DOSE‐RESPONSE STUDY OF COLESTIPOL TABLETS IN PATIENTS WITH MODERATE HYPERCHOLESTEROLEMIA

P. Greenland, D. Hunninghake, E. Stein, 1995, American journal of therapeutics.

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.

S. Grundy, J. Cleeman, Sidney C. Smith, 2004, Journal of the American College of Cardiology.

National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)

J. Mckenney, M. Proschan, S. Grundy, 2015 .

Evaluation of implementation of a cholesterol management program in physicians' offices.

K. Glanz, D. Hunninghake, M. Brekke, 1992, Health Education Research.

The Association of Plasma High‐density Lipoprotein Cholesterol with Dietary Intake and Alcohol Consumption: The Lipid Research Clinics Program Prevalence Study

D. Hunninghake, B. Rifkind, David, 1980 .

Inhibitors of Cholesterol Synthesis and Cataracts-Reply

R. Palmer, D. Hunninghake, G. Schonfeld, 1987 .

Altered platelet deformability in patients with type IIa and type IV hyperlipoproteinemia

D. Hunninghake, J. White, S. Burris, 1988, American journal of hematology.

Appropriate days for measuring intake of dietary fat and cholesterol.

R. Mullis, D. Hunninghake, J. Peters, 1992, Annals of nutrition & metabolism.

Long‐Term Effects of Clofibrate (Atromid‐S) on Serum Lipids in Man

D. R. Tucker, D. Hunninghake, D. Azarnoff, 1969, Circulation.